This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Peanut allergy treatments: What’s next for the field?

Ticker(s): AIMT, DBVT

Who's the expert?

Name: Dr Erwin Gelfand - MD

Institution: National Jewish Health

  • Pediatric allergist and immunologist and Professor of Pediatrics at National Jewish Health in Denver.
  • Currently treats more than 200 patients with PIDD.
  • Clinical interests include the diagnosis and treatment of immune deficiency and autoimmune disorders and severe atopic diseases; has received numerous grants from the National Institutes of Health, the Environmental Protection Agency and several foundations, and has published more than 750 papers in peer-reviewed journals.

Interview Goal
Multiple companies are now developing new treatments aimed at protecting people with severe peanut allergies. On Sept. 13, an FDA advisory committee will meet to discuss an “oral challenge” treatment developed by Aimmune Therapeutics (AIMT). There’s also a competing treatment in development by DBV Technologies (DBVT). STAT’s Adam Feuerstein will join a leading allergist to outline the issues related to treating patients with severe peanut allergies, the questions about the tolerability and safety of Aimmune’s AR101, and competing immunotherapy data from DBV.

Are You Interested In These Questions?

6Days Left to Join Project
Call Date
Aug 28, 2019
Call Time
11:00 AM EDT
Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.